Back

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough: Chairpersons conclusion

3 March 2018 (14:40 - 14:45)
Organised by:
Congress Presentation Part of: Controversies on anticoagulants post-MI antithrombotic treatment Acute Coronary Syndromes: Post-Infarction Period ACVC Premium Access Acute Cardiovascular Care 2018

9 More presentations in this session

Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - PRO.
Doctor A. Rubboli (Ravenna, IT)
Slides Video
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - CONTRA.
Professor R. Storey (Sheffield, GB)
Slides Video
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal PRO.
Doctor A. Rubboli (Ravenna, IT)
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal CONTRA.
Professor R. Storey (Sheffield, GB)
Presentation thumbnail
All stented patients with atrial fibrillation, stable one year after intervention, should be managed with oral anticoagulants, without antiplatelets - PRO.
Professor R. De Caterina (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
Controversies on anticoagulants post-MI antithrombotic treatment

The Event

Event poster

Acute Cardiovascular Care 2018

3 March 2018 14:40 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources